



Corticosteroid therapy in fibrotic interstitial lung disease: a modified Delphi survey

Copyright ©The authors 2024

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

Received: 31 May 2024
Accepted: 5 June 2024

To the Editor:


Fibrotic interstitial lung diseases (fILD) may have features that suggest inflammatory processes that contribute to disease pathogenesis [1]. A recent systematic review shows that the effectiveness and safety of steroid therapy in fILD are still inadequately understood [2], while steroids are potentially harmful in idiopathic pulmonary fibrosis (IPF) [3]. We performed a modified Delphi survey with the objectives of achieving global expert consensus on the indications and role of steroids in treating patients with fILD, and of highlighting future research priorities, while recognising that robust evidence is lacking. This study excluded IPF, systemic sclerosis-associated interstitial lung disease (ILD), sarcoidosis, and ILD treatment in the context of acute exacerbations.

We undertook a qualitative literature review to inform the initial round of the survey, focused on previous definitions of inflammation in fILD, and proposed indications for steroids. The study team then finalised the initial set of statements for inclusion. The surveys were undertaken between August and October 2023. Survey participants were identified from the REMAP-ILD consortium and the Swiss special interest group for ILD and were invited *via* email to complete the surveys. Statements focused on clinical, laboratory, radiological and histological findings that have been proposed to represent inflammation. Statements also focused on the clinical indications for corticosteroids, and dosing, delivery as well as duration of corticosteroids, to treat patients with fILD.

Using a modified Delphi method, participants were provided statements on defining, assessing and treating inflammation in fILD. Each statement was rated on a 5-point Likert scale (strongly disagree, disagree, unsure, agree, or strongly agree). Consensus for agreement required at least 75% agreement (agree or strongly agree), and for disagreement at least 75% disagreement (disagree or strongly disagree). If consensus was not achieved in the first round, statements were revised and reissued with prior round results. Additional statements were generated based on first-round feedback. Two multiple-choice questions on the definition of pulmonary inflammation and defining and predicting steroid responsiveness were added in the second round to contextualise the results. Data were collected and analysed using secure online survey platforms (SurveyMonkey, Momentive Inc.), ensuring participant confidentiality.

In the initial round, 164 participants were invited, of whom 56 (34%) completed the survey. Additional participants were invited to the second round to increase representation: 206 participants were invited, with 67 (33%) completing the survey. Most (95%) were pulmonologists, with two radiologists and one rheumatologist; a large majority of respondents were from Europe (73%), with a minority from North America (18%), South America (3%), Oceania (1%) and Asia (1%). 13 statements were included in the first round, and 10 in the second round. After two rounds of the survey, nine statements met consensus for agreement and one met consensus for disagreement.

As shown in figure 1, participants agreed that clinical signs suggestive of pulmonary inflammation inform their clinical decision-making for steroid therapy. Most participants agreed that high-resolution computed tomography (HRCT) should be performed prior to initiating steroid therapy, and that lung function measurements should be performed at baseline to inform treatment response, but lung biopsies are not required and should not be performed for this reason.



Shareable abstract (@ERSpublications)

The use of steroids in fibrotic interstitial lung diseases is founded on limited evidence. This modified Delphi survey sheds light on current clinical practices. Given the risks of steroids, clinical trials are needed to evaluate efficacy and harm. <https://bit.ly/3VkgvBS>

Cite this article as: Funke-Chambour M, Suter P, Jenkins GR, *et al.* Corticosteroid therapy in fibrotic interstitial lung disease: a modified Delphi survey. *ERJ Open Res* 2024; 10: 00561-2024 [DOI: 10.1183/23120541.00561-2024].




FIGURE 1 Overview of the survey statements that were evaluated by the participants. fILD: fibrotic interstitial lung diseases; CT: computed tomography; HRCT: high-resolution CT; BAL: bronchoalveolar lavage; D_{LCO} : diffusing capacity of the lung for carbon monoxide; GGO: ground glass opacity; MDA5: melanoma differentiation-associated protein 5.

Participants agreed that bronchoalveolar lavage (BAL) and HRCT findings might suggest pulmonary inflammation. BAL fluid lymphocytosis >30%, radiological findings of ground glass opacity (GGO), consolidation or GGO in areas without traction bronchiectasis could indicate steroid responsiveness.

Participants agreed that if steroid treatment is initiated in patients with fILD, the oral route is preferred, initial doses being proposed at 10–50 mg·day⁻¹, adapted to comorbidities and risk profile. Participants suggested steroid therapy should be reviewed within the first 3 months to assess for adverse effects, response to therapy, and potential tapering/discontinuation.

In this international modified Delphi survey, consensus was achieved on three domains: 1) clinical indicators that may represent pulmonary inflammation, 2) how clinicians anticipate response to steroid therapy, and 3) how steroids are prescribed and managed in patients with fILD. That consensus was achieved for several statements highlights the desire for clinicians to treat potentially treatable traits despite an absence of evidence. While consensus represents agreement in the three domains, it does not replace the need for robust objective data, and the findings herein highlight heterogeneity in clinical practice with the urgent need for prospective randomised clinical trials to address these questions.

Despite the unclear definition of pulmonary inflammation, our survey found that clinicians consider it a potentially treatable trait. According to our survey results, participants agreed that pulmonary inflammation is suggested by the presence of GGO on HRCT, although it can represent alveolar oedema, air trapping, haemorrhage and fine reticulation. Similarly, BAL lymphocytosis was considered a reason for treatment with steroids in the absence of high-quality evidence that BAL lymphocytosis reflects a specific steroid-responsive cellular subpopulation. Limitations of available data that currently guide decision-making include their retrospective non-randomised study designs and considerable residual confounding [4–7]. However, use of BAL lymphocytosis as a marker is supported by recent data showing that elevated BAL lymphocytes were associated with lower probability of disease progression in patients with limited fibrosis or lack of usual interstitial pneumonia pattern on HRCT [8]. While systemic blood biomarkers for inflammation may be identified in patients with fILD [9], none are sufficiently validated to justify clinical implementation.

HRCT was suggested as a mandatory test prior to steroid treatment, suggesting that radiological findings strongly inform management decisions despite the broad differential for the radiological features considered to associate with inflammation. Previous studies used radiological HRCT patterns to identify steroid-sensitive patients in connective tissue disease-associated ILD (CTD-ILD) [10]. Participants did not

agree on performing BAL, although, if performed, lymphocytosis was considered to support steroid responsiveness [6, 7]. There was, however, agreement that lung biopsies do not predict treatment response and, given their risk profile, should be considered judiciously.

Steroid treatment is often prescribed first-line in patients with progressive fILD other than IPF [11, 12], such as hypersensitivity pneumonitis [13] and CTD-ILD, based on limited evidence, but when the fibrotic component of the ILD predominates, no effect of corticosteroid treatment has been shown [6, 14]. There is no support for steroid use in IPF patients, and even potentially harmful effects [3]. If used in non-IPF fILD, the dose regimens vary widely, with limited evidence of low certainty [2]. There are no protocols or international recommendations regarding dosage and administration for fILD patients, although steroid treatment is suggested for various subtypes [15]. Despite the lack of high-quality evidence, our survey suggests that most experts agree on the use of moderate doses of steroids in fILD suspected to be inflammatory, with re-evaluation after 3 months. This highlights that steroids are being broadly used despite absence of evidence and, given the known harms of this therapy, a clinical trial is urgently required.

No consensus was achieved on whether steroids would be appropriate in the absence of pulmonary inflammation, even when the associated underlying disease is known to be inflammatory (*e.g.* CTD-ILD), whether BAL should always be performed prior to steroid initiation, and whether BAL lymphocytosis of 20–30% provides support for steroid treatment in fILD. The lack of consensus highlights important areas for future research to define pulmonary inflammation more accurately and to establish the role of BAL to inform management decisions.

This study has limitations. Most participants responding to the survey were from Europe, potentially limiting generalisability. The relatively low response rate may introduce selection bias. Nuances of steroid therapy, including individual case management, could not be ascertained and these results present a general overview of expert opinion. Most importantly, consensus through the Delphi process does not replace the need for objective evidence. Each topic presented herein should be further evaluated in the context of prospective randomised controlled trials, to robustly inform effectiveness and safety. Additional stakeholder views including those of rheumatologists, radiologists and patients should be explored in future work.

Manuela Funke-Chambour ¹, **Philipp Suter**¹, **Gisli R. Jenkins**², **Leticia Kawano-Dourado** ³, **Christopher J. Ryerson**⁴, **Athol U. Wells**⁵, **Michael Kreuter**^{6,7,9}, **Kerri A. Johannson**^{8,9} and **the Delphi Survey Participants**

¹Department for Pulmonology, Allergology and Clinical Immunology, Inselspital, University Hospital Bern, Bern, Switzerland. ²Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, Imperial College London, London, UK. ³Hcor Research Institute, Hospital do Coracao, Sao Paulo, Brazil and Pulmonary Division, Heart Institute (InCor), University of Sao Paulo, Sao Paulo, Brazil. ⁴Department of Medicine and Centre of Heart Lung Innovations, University of British Columbia, Vancouver, BC, Canada. ⁵Royal Brompton and Harefield NHS Foundation Trust, London, UK. ⁶Mainz Center for Pulmonary Medicine, Department of Pneumology, Mainz University Medical Center, Mainz, Germany. ⁷Department of Pulmonary, Critical Care and Sleep Medicine, Marienhaus Clinic Mainz, Mainz, Germany. ⁸Department of Medicine, University of Calgary, Calgary, AB, Canada. ⁹These authors contributed equally.

Corresponding author: Michael Kreuter (kreuterm@uni-mainz.de)

Provenance: Submitted article, peer reviewed.

Delphi survey participants: Participants that agreed to be named and indicated their names are listed as collaborators and are members of the REMAP-ILD consortium or the special interest group for ILD of the Swiss Society for Pulmonology. Ayodeji Adegunsotoye (USA), Dan Adler (Switzerland), Andrea Azzola (Switzerland), Shaney Barratt (UK), Iazsmin Bauer Ventura (USA), Bruno Guedes Baldi (Brazil), Elisabeth Bendstrup (Denmark), Francesco Bonella (Germany), Raphael Borie (France), Pierre-Olivier Bridevaux (Switzerland), Martin Brutsche (Switzerland), Diego Castillo (Spain), Nazia Chaudhuri (UK), Christian Clarenbach (Switzerland), Tamera Corte (Australia), Vincent Cottin (France), Anjali Crawshaw (UK), James Eaden (UK), Laura Fabbri (UK), Jean-Marc Fellrath (Switzerland), Daniel Franzen (Switzerland), Sophie V. Fletcher (UK), Peter George (UK), Amanda Goodwin (UK), Sabina Guler (Switzerland), Ena Gupta (USA), Chris Grainge (Australia), Sandor Györök (Switzerland), Kirsty Hett (UK), Markus Hofer (Switzerland), Katrin Hostettler (Switzerland), Gary M. Hunninghake (USA), Christopher C. Huntley (UK), Simon Hart (UK), Nik Hirani (UK), Kathleen Jahn (Switzerland), Marc Jones (UK), Bhavika Kaul (USA), Tejaswini Kulkarni (USA), Killian Hurley (Ireland), Joseph Jacob (UK), Michael P. Keane (Ireland), Fasihul Khan (UK), Yet Hong

Khor (Australia), Joyce Lee (USA), Sara Piciucchi (Italy), Susanne Pohle (Switzerland), Pilar Rivera-Ortega (UK), Dieter Scholtze (Switzerland), Jacobo Sellares (Spain), Mark Spears (UK), Lisa Spencer (UK), Irina Strambu (Romania), Jeff Swigris (USA), Reoto Takei (Japan), Athina Trachalaki (UK), Argyris Tzouveleakis (Greece), Marlies Wijsenbeek (the Netherlands), Andrew Wilson (UK), Wim Wuyts (Belgium) and Tanzira Zaman (USA).

Conflicts of interest: M. Funke-Chambour declares grants or contracts from Boehringer Ingelheim, consultancy and speaker's fees from Boehringer Ingelheim, Roche, MSD, AstraZeneca, Pfizer, GSK and Sanofi, outside this project. P. Suter has nothing to disclose. G.R. Jenkins declares grants to his institution from AstraZeneca, Biogen, Galacto, GlaxoSmithKline, Nordic Biosciences, RedX and Pliant, consultancy fees from AbbVie, Apollo Therapeutics, AstraZeneca, Brainomix, Bristol Myers Squibb, Chiesi, Cohbar, Daewoong, GlaxoSmithKline, Resolution Therapeutics and Pliant, honoraria from Boehringer Ingelheim, Chiesi, Roche, PatientMPower and AstraZeneca, payment for expert testimony from Pinsent Masons LLP, and participation on data safety or advisory board for Boehringer Ingelheim, Galapagos and Vicore, outside this project. L. Kawano-Dourado declares grants paid to their institution from Boehringer Ingelheim and Bristol Myers Squibb, and consultancy fees from Boehringer Ingelheim, outside this project. C.J. Ryerson declares grants from Boehringer Ingelheim paid to his institution, consultancy fees from Boehringer Ingelheim, Pliant Therapeutics, AstraZeneca, Trevi Therapeutics and Veracyte, payment or honoraria for lectures or presentations from Hoffmann-La Roche and Boehringer Ingelheim, and payment for expert testimony and travel support from Boehringer Ingelheim, outside this project. A.U. Wells reports consultancy fees from Roche, and payment or honoraria for lectures or presentations from Boehringer Ingelheim and Veracyte, and is President of the World Association of Sarcoidosis and Other Granulomatous Diseases, outside of the submitted work. M. Kreuter declares grants or contracts and royalties or licenses from Boehringer Ingelheim and Roche, consulting fees from Nichtraucherhelden/Sanero, Boehringer Ingelheim, Roche, BMS, GSK and AstraZeneca, and a leadership or fiduciary role for the European Respiratory Society, outside this project. K.A. Johansson declares grants paid to her institution from the University Hospital Foundation and the Three Lakes Foundation, consulting fees from Boehringer Ingelheim, Roche, Pliant Therapeutics and Brainomix, payment or honoraria for lectures or presentations and travel support from Boehringer Ingelheim, participation on a Data Safety Monitoring Board for the PFOX trial, and a stock option from Thyron SAB, outside this project.

References

- 1 Koudstaal T, Funke-Chambour M, Kreuter M, *et al.* Pulmonary fibrosis: from pathogenesis to clinical decision-making. *Trends Mol Med* 2023; 29: 1076–1087.
- 2 Pitre T, Kawano-Dourado L, Kachkovski GV, *et al.* Systemic corticosteroids in fibrotic lung disease: a systematic review and meta-analysis. *BMJ Open Respir Res* 2023; 10: e002008.
- 3 Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, *et al.* Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. *N Engl J Med* 2012; 366: 1968–1977.
- 4 Behr J, Salisbury ML, Walsh SLF, *et al.* The role of inflammation and fibrosis in interstitial lung disease treatment decisions. *Am J Respir Crit Care Med* 2024; 210: 392–400.
- 5 Meyer KC, Raghu G, Baughman RP, *et al.* An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. *Am J Respir Crit Care Med* 2012; 185: 1004–1014.
- 6 De Sadeleer LJ, Hermans F, De Dycker E, *et al.* Impact of BAL lymphocytosis and presence of honeycombing on corticosteroid treatment effect in fibrotic hypersensitivity pneumonitis: a retrospective cohort study. *Eur Respir J* 2020; 55: 1901983.
- 7 Yamagata A, Arita M, Tachibana H, *et al.* Impact of bronchoalveolar lavage lymphocytosis on the effects of anti-inflammatory therapy in idiopathic non-specific interstitial pneumonia, idiopathic pleuroparenchymal fibroelastosis, and unclassifiable idiopathic interstitial pneumonia. *Respir Res* 2021; 22: 115.
- 8 Barnett JL, Maher TM, Quint JK, *et al.* Combination of BAL and computed tomography differentiates progressive and non-progressive fibrotic lung diseases. *Am J Respir Crit Care Med* 2023; 208: 975–982.
- 9 Cai M, Bonella F, He X, *et al.* CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases. *Respir Med* 2013; 107: 1444–1452.
- 10 Feng DY, Zhou YQ, Xing YF, *et al.* Selection of glucocorticoid-sensitive patients in interstitial lung disease secondary to connective tissue diseases population by radiomics. *Ther Clin Risk Manag* 2018; 14: 1975–1986.
- 11 Nili M, Singer D, Hanna M. Care patterns of patients with chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype. *BMC Pulm Med* 2022; 22: 153.
- 12 Wijsenbeek M, Kreuter M, Olson A, *et al.* Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. *Curr Med Res Opin* 2019; 35: 2015–2024.
- 13 Kokkarinen JI, Tukiainen HO, Terho EO. Effect of corticosteroid treatment on the recovery of pulmonary function in farmer's lung. *Am Rev Respir Dis* 1992; 145: 3–5.
- 14 De Sadeleer LJ, Hermans F, De Dycker E, *et al.* Effects of corticosteroid treatment and antigen avoidance in a large hypersensitivity pneumonitis cohort: a single-centre cohort study. *J Clin Med* 2018; 8: 14.
- 15 Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. *N Engl J Med* 2020; 383: 958–968.